María Eugenia
Alonso Sarasquete
Investigadora desde 2011
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (10)
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Blood Cancer Journal, Vol. 10, Núm. 2
2018
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2017
-
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106
-
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array
Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751
2016
-
Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma
Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217
2015
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
-
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
Leukemia